The Company

Dexcom Corporation (NASDAQ DXCM) is a pioneer and global leader in continuous glucose monitoring (CGM). Dexcom began as a small company with a big dream: To forever change how diabetes is managed. To unlock information and insights that drive better health outcomes. Here we are 25 years later, having pioneered an industry. And we're just getting started. We are broadening our vision beyond diabetes to empower people to take control of health. That means personalized, actionable insights aimed at solving important health challenges. To continue what we've started: Improving human health.

We are driven by thousands of ambitious, passionate people worldwide who are willing to fight like warriors to earn the trust of our customers by listening, serving with integrity, thinking big, and being dependable. We've already changed millions of lives and we're ready to change millions more. Our future ambition is to become a leading consumer health technology company while continuing to develop solutions for serious health conditions. We'll get there by constantly reinventing unique biosensing-technology experiences. Though we've come a long way from our small company days, our dreams are bigger than ever. The opportunity to improve health on a global scale stands before us.

Meet the team:

Release Engineering builds cost-efficient AI platforms for product teams and internal developers. We operate traditional ML and generative AI models at scale on GCP/GKE, automate model delivery, and manage usage across self-hosted and external providers. We partner with ML Engineering on model quality and training, and AI Engineering on application behavior. You will contribute with guidance from experienced engineers.

Where you come in:

You will help operate models on GKE, including vLLM serving; track cost per request and token at scale.
You will maintain AI router configurations using tools such as LiteLLM for provider integration, routing, and fallbacks.
You will support internal developer access, team budgets, usage limits, and cost reporting across providers such as Vertex AI and OpenAI.
You will build CI/CD automation for model pipelines, registry promotion, testing, deployment, and rollback.
You will maintain infrastructure as code and GitOps configurations for repeatable cloud and Kubernetes changes.
You will track per-model tokens, cache hits, and resource usage; help tune caching, batching, and autoscaling to reduce cost within quality and reliability targets.
You will troubleshoot serving and pipeline issues with teammates; maintain tests and runbooks.

What makes you successful:

You have python, Git, and automated testing skills demonstrated through projects, internships, or professional work.
You have foundational knowledge of Linux, containers, Kubernetes, and GCP.
You have understanding of CI/CD, infrastructure as code, and model-delivery workflows; exposure to Terraform, Pulumi, or equivalent tools is helpful.
You have interest in AI usage accounting, cloud cost efficiency, and multi-provider APIs; LiteLLM or model-serving exposure is helpful.
You have systematic troubleshooting, clear communication, and a willingness to learn.

What you’ll get:

· A front row seat to life changing CGM technology. Learn about our brave #dexcomwarriors community.

· A full and comprehensive benefits program.

· Growth opportunities on a global scale.

· Access to career development through in-house learning programs and/or qualified tuition reimbursement.

· An exciting and innovative, industry-leading organization committed to our employees, customers, and the communities we serve.

Travel Required:

Experience and Education Requirements:

· Typically requires a bachelor's degree in a technical discipline, and a minimum of 0-2 years of related experience.

Flex Workplace: Your primary location will be a home office. You will not have an assigned workstation and will work with your manager to determine office visit needs. You must live within commuting distance of your assigned Dexcom site (typically 75 miles/120km).

Please note: The information contained herein is not intended to be an all-inclusive list of the duties and responsibilities of the job, nor are they intended to be an all-inclusive list of the skills and abilities required to do the job. Management may, at its discretion, assign or reassign duties and responsibilities to this job at any time. The duties and responsibilities in this job description may be subject to change at any time due to reasonable accommodation or other reasons. Reasonable accommodations may be made to enable individuals with disabilities to perform essential functions.

An Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, age, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Dexcom’s AAP may be viewed upon request by contacting Talent Acquisition at [email protected].

If you are an individual with a disability and would like to request a reasonable accommodation as part of the employment selection process, please contact Dexcom Talent Acquisition at [email protected].

Meritain, an Aetna Company, creates and publishes the Machine-Readable Files on behalf of Dexcom. To link to the Machine-Readable Files, please click on the URL provided: https://health1.meritain.com/app/public/#/one/insurerCode=MERITAIN_I&brandCode=MERITAINOVER/machine-readable-transparency-in-coverage?reportingEntityType=TPA_19874&lock=true

To all Staffing and Recruiting Agencies: Our Careers Site is only for individuals seeking a job at Dexcom. Only authorized staffing and recruiting agencies may use this site or to submit profiles, applications or resumes on specific requisitions. Dexcom does not accept unsolicited resumes or applications from agencies. Please do not forward resumes to the Talent Acquisition team, Dexcom employees or any other company location. Dexcom is not responsible for any fees related to unsolicited resumes/applications.

AI in Hiring Notice: We may use AI supported tools to help make our hiring process more efficient, consistent, and accessible for candidates around the world. All hiring decisions are made by people.

Salary:

$68,200.00 - $113,600.00

#DexcomUS

About the company

Dexcom develops continuous glucose monitoring systems to help people manage diabetes by giving real-time glucose readings. Its main product, the Dexcom G6 CGM System, uses a wearable sensor and transmitter to send data to a display device or smartphone without requiring finger-prick calibrations. The company also offers Dexcom CLARITY analytics software and subscription services to manage and share glucose data with clinicians and caregivers. Dexcom differentiates itself with a complete CGM ecosystem that combines real-time data, a factory-calibrated sensor, and integrated analytics and data-sharing features to support patients, families, and healthcare providers, with a goal of improving quality of life for people with diabetes through accurate, easy-to-use monitoring and actionable insights.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Get referred to Dexcom

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue rose 13% to $1.308 billion, and guidance increased to $5.25 billion.
Gross margin reached 64.1% in Q2 2026, helped by manufacturing efficiencies and 15-day conversion.
Health2Sync expansion into Australia and Singapore broadens Dexcom's international digital-care distribution in 2026.

What critics are saying

Dexcom faces 11 G7 and G6 lawsuits, including child hospitalizations, through October 2026.
FDA classified 2026 G7 recalls for stolen scrap lots and watchOS software defects.
Abbott still leads CGM share; a severe G7 trust failure threatens Dexcom's franchise.

What makes Dexcom unique

Dexcom G7 15-day launched in 2025, lifting retention and margin economics in 2026.
Dexcom secured G7 15-day clearance in Canada, expanding regulatory reach beyond the U.S.
Dexcom pairs hardware with CLARITY and Health2Sync, building sticky diabetes workflow integration.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Professional Development Budget
Remote Work Options
Flexible Work Hours
Tuition Reimbursement

Growth & Insights and Company News

6 month growth

1 year growth

-1%

2 year growth

Yahoo Finance

Oct 29th, 2026

DexCom lifts 2026 revenue outlook to $5.25B after 11% Q3 growth to $1.34B

DexCom reported third-quarter revenue of $1.34 billion, up 11% from a year earlier. US revenue rose 14% to $970 million, while international revenue grew 5% to $375 million. The glucose monitor maker raised its full-year revenue outlook to $5.20 billion–$5.25 billion. It now expects an adjusted operating margin of about 24% and an adjusted EBITDA margin of about 32%. Net income was $275 million, or $0.73 per share. Gross margin rose to 65.1% from 61.3%, helped by manufacturing efficiencies and lower freight costs. DexCom authorised an extra $1 billion share buyback after completing a $1 billion repurchase this year. It expects Medicare to decide on wider coverage for type 2 diabetes patients not using insulin, with any change taking effect in mid-2027.

Yahoo Finance

Oct 28th, 2026

DexCom Q3 preview: 9.9% revenue growth expected after $1.31B beat last quarter

DexCom (NASDAQ:DXCM) will report third-quarter results on Thursday after the bell. Analysts expect revenue to grow 9.9% year on year, slowing from 21.6% in the same quarter last year. Last quarter, the medical device company reported revenue of $1.31 billion, up 13.1% and ahead of estimates. It also beat analysts' EPS estimates and has a history of topping Wall Street expectations. Among peers, Intuitive Surgical grew revenue 21.7% and Neogen 6.5%. Both beat estimates, yet each traded down 2.3% afterwards. DexCom shares have fallen 9% over the past month, against an average 3.6% rise for the sector. The stock trades at $78.84, versus an average analyst price target of $96.19.

AD HOC NEWS

Oct 20th, 2026

Piper Sandler sets USD 160.00 target for iRhythm stock.

Piper Sandler sets USD 160.00 target for iRhythm stock. Published on 10/20/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Piper Sandler sets a USD 160.00 target on October 16, 2026. iRhythm stock costs EUR 101.50 on October 20, 2026, up 4.25 percent on Nasdaq. Analyst coverage and trading. * Piper Sandler began coverage with a USD 160.00 target on October 16, 2026. * Second-quarter revenue reached USD 224.17 million, up 20.1 percent year over year. * iRhythm stock costs EUR 101.50 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST, with Nasdaq trading up 4.25 percent. * Third-quarter results are scheduled for November 5, 2026. iRhythm Technologies (ISIN US4500561067) drew a USD 160.00 price target when MarketScreener reported Piper Sandler's new Overweight rating on October 16, 2026. The target stands 40.04 percent above the Nasdaq price of USD 114.25 at 3:51 p.m. ET on October 20, 2026. After hours, the stock was trading at EUR 101.50 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST, while Nasdaq trading was up 4.25 percent. Revenue reached USD 224.17 million. The latest reported quarter gives the analyst view an operating anchor. According to iRhythm, revenue in the second quarter of 2026 reached USD 224.17 million, up 20.10 percent from USD 186.69 million in the second quarter of 2025. Gross margin rose to 72.80 percent from 71.20 percent, while adjusted EBITDA increased to USD 43.30 million from USD 15.70 million. The quarter also marked a sharp improvement in adjusted profitability. Adjusted net income was USD 19.32 million in the second quarter of 2026, compared with an adjusted net loss of USD 10.22 million in the same quarter of 2025. Stock remains near its yearly low. The Nasdaq quote places iRhythm at USD 114.25, versus a 52-week range of USD 100.70 to USD 212.00 as of October 20, 2026. The price therefore stood 43.16 percent below the yearly high and 13.45 percent above the yearly low. The market capitalization was USD 3.8 billion, with 379,512 shares traded by 3:51 p.m. ET. Valuation and next reporting date. For comparison, DexCom traded at USD 85.71 on October 20, 2026, down 0.31 percent, with a price-to-earnings ratio of 33.86 and market capitalization of USD 32.3 billion. Insulet traded at USD 142.87, up 0.64 percent, with a price-to-earnings ratio of 26.70 and market capitalization of USD 9.9 billion. MarketScreener lists November 5, 2026 as the date for iRhythm's third-quarter 2026 financial results. The USD 160.00 target from October 16, 2026 remains the clearest dated analyst reference in the current trading picture. Price and analyst target. The euro quote and the Nasdaq price describe separate venues, but both place the stock well below Piper Sandler's USD 160.00 target. The next results date will provide the next formal test of the company's USD 880 million to USD 890 million full-year 2026 revenue outlook. The further course of trading is shown by the continuously updated real-time quote of iRhythm stock. iRhythm Technologies market data. * Company: iRhythm Technologies, Inc. * ISIN: US4500561067 * Ticker: IRTC * Primary exchange: Nasdaq * Price Lang & Schwarz as of October 20, 2026, 9:45 p.m. CEST: EUR 101.50 * Change on Nasdaq: plus 4.25 percent as of October 20, 2026 * Market capitalization: USD 3.8 billion as of October 20, 2026 * 52-week range: USD 100.70-212.00 as of October 20, 2026 * Sector / Industry: Healthcare / Medical Devices * Next earnings date: November 5, 2026 Sponsored Ad iRhythm stock: new analysis - 22 October. Fresh iRhythm information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US4500561067 | IRMD | boerse | 70378236 | bgmi

John Paul Construction

Oct 19th, 2026

Three awards for rosslare Europort and Dexcom projects.

Three awards for rosslare Europort and Dexcom projects. Date: October 19, 2026 Two John Paul Construction projects were recognised at this year's Irish Construction Industry Awards, receiving awards across three categories. Rosslare Europort Terminal 7 was named Civil Construction Project of the Year, while the Dexcom Manufacturing Facility in Athenry received both Industrial Project of the Year and the overall Project of the Year awards. These awards recognise the expertise, commitment and collaboration that contributed to the successful delivery of both projects. They also reflect the strong partnerships between its project teams, clients, design consultants and supply chain partners throughout each project lifecycle.

HookPhish

Oct 10th, 2026

Ransomware Group Redact hits: dexcom.

Ransomware Group Redact hits: dexcom. HookPhish team Target organization DexCom dexcom.com Healthcare Summary. In the latest cybersecurity news, DexCom - an organization based in US - has fallen victim to a ransomware attack conducted by the group Redact. This data breach, discovered on Oct 10, 2026, 16:53 UTC, underscores the increasing need for proactive cybersecurity defenses as HookPhish continue through 2026. Incident report. | Target Organization | DexCom | | Threat Group | Redact | | Summary | Sector: Medical Equipment | Revenue: $4.97B USD | | Date of Breach | Oct 10, 2026, 16:53 UTC | | Discovery Date | Oct 10, 2026, 16:53 UTC | | Region | US | | Target Domain | dexcom.com | | Business Sector | Healthcare | How to reduce your ransomware risk. Most ransomware intrusions start with a stolen password or a phishing email. A few proactive steps sharply cut your exposure: * security awareness training - close the gap attackers exploit. * dark web monitoring - close the gap attackers exploit. Disclaimer. HookPhish does not engage in the exfiltration, downloading, taking, hosting, viewing, reposting, or disclosure of any stolen information. All breach data reported here is sourced from publicly available threat intelligence feeds for awareness purposes only.

Dexcom

Software Development Engineer 1

About the job